About this FactMed analysis covering adverse side effect reports of CLOFAZIMINE patients who developed ACHLORHYDRIA.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 1 individuals taking CLOFAZIMINE reported ACHLORHYDRIA to the FDA. A total of 136 CLOFAZIMINE drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between CLOFAZIMINE and ACHLORHYDRIA. In doing so, we compare CLOFAZIMINE with other drugs that cause ACHLORHYDRIA, to help you evaluate whether or not CLOFAZIMINE causes ACHLORHYDRIA. Likewise, this page shows the most highly-reported side effects of CLOFAZIMINE, so you can see if ACHLORHYDRIA ranks among CLOFAZIMINE's most well-known side effects.
Summary Statistics
Reports of CLOFAZIMINE causing ACHLORHYDRIA: 1
Reports of any side effect of CLOFAZIMINE : 136
Percentage of CLOFAZIMINE patients where ACHLORHYDRIA is a reported side effect: 0.7353%

FDA reports of any drug causing ACHLORHYDRIA : 27
Average percentage for all medicated patients where ACHLORHYDRIA is reported as a complication: 0.0002%

Physician opinion on CLOFAZIMINE as adverse event culprit:

Overall opinion for all reports of this drug:
Most frequent diagnoses/indications for prescribing CLOFAZIMINE:
LEPROSY ( 21 patients )
LEPROMATOUS LEPROSY ( 14 patients )
PYODERMA GANGRENOSUM ( 8 patients )
TUBERCULOSIS ( 7 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 7 patients )
ERYTHEMA NODOSUM LEPROSUM ( 3 patients )
PULMONARY TUBERCULOSIS ( 2 patients )
BORDERLINE LEPROSY ( 2 patients )
ILL-DEFINED DISORDER ( 2 patients )
MYCOBACTERIUM AVIUM COMPLEX INFECTION ( 2 patients )
TUBERCULOID LEPROSY ( 2 patients )
TYPE 2 LEPRA REACTION ( 2 patients )
NODULAR VASCULITIS ( 2 patients )
SKIN LESION ( 1 patients )
MELKERSSON-ROSENTHAL SYNDROME ( 1 patients )
ANTI-INFECTIVE THERAPY ( 1 patients )
LYMPH NODE TUBERCULOSIS ( 1 patients )
MYCOBACTERIUM ABSCESSUS INFECTION ( 1 patients )
( 0 patients )
Drugs with high FDA adverse event association with ACHLORHYDRIA:

ASPIRIN (8 patients)
AMLODIPINE (7 patients)
COREG (6 patients)
COUMADIN (6 patients)
FLUCONAZOLE (6 patients)
GLUCOVANCE (6 patients)
GLYBURIDE (6 patients)
LASIX (6 patients)
LEVAQUIN (6 patients)
LIPITOR (6 patients)
PROMETHAZINE (6 patients)
SEROQUEL (6 patients)
AMOXICILLIN (5 patients)
CARVEDILOL (5 patients)
CIPROFLOXACIN (5 patients)
CYANOCOBALAMIN (5 patients)
DIGOXIN (5 patients)
DOXYCYCLINE (5 patients)
FOSINOPRIL SODIUM (5 patients)
GABAPENTIN (5 patients)
LISINOPRIL (5 patients)
LORCET-HD (5 patients)
MELOXICAM (5 patients)
METOLAZONE (5 patients)
NEXIUM (5 patients)
OMEPRAZOLE (5 patients)
OXYCODONE HCL AND ACETAMINOPHEN (5 patients)
ACULAR (4 patients)
GEMFIBROZIL (4 patients)
MUPIROCIN OINTMENT (4 patients)
NEORAL (4 patients)
POTASSIUM CHLORIDE (4 patients)
SILVASORB (4 patients)
TEMAZEPAM (4 patients)
TRIMETHO SULFAMETHOX (4 patients)
ACTOS (3 patients)
AGGRENOX (3 patients)
GLUCOPHAGE (3 patients)
KLOR-CON (3 patients)
LANSOPRAZOLE (3 patients)
SODIUM BICARBONATE (3 patients)
CODEINE (2 patients)
COZAAR (2 patients)
FUROSEMIDE (2 patients)
HYDROCODONE (2 patients)
MUPIROCIN (2 patients)
PANTOPRAZOLE SODIUM (2 patients)
PEG (2 patients)
POTASSIUM (2 patients)
PRILOSEC OTC (2 patients)
PROPO-K (2 patients)
RANITIDINE (2 patients)
SIMVASTATIN (2 patients)
SPIRIVA (2 patients)
SULFAMETHOXAZOLE AND TRIMETHOPRIM (2 patients)
WARFARIN SODIUM (2 patients)
ZANTAC (2 patients)
ACETYLSALICYLIC ACID SRT (1 patients)
ADVAIR HFA (1 patients)
ALBUTEROL SULFATE AUTOHALER (1 patients)
ALCOHOL (1 patients)
ALLEGRA (1 patients)
AMOXICILLIN+CLAVULANATE (1 patients)
ATENOLOL (1 patients)
AZITHROMYCIN (1 patients)
BUPROPION HCL (1 patients)
CALCIUM SUPPLEMENTS (1 patients)
CHLORTHALIDONE (1 patients)
CLOFAZIMINE (1 patients)
CLONAZEPAM (1 patients)
CLOTRIMAZOLE (1 patients)
COCAINE (1 patients)
COMBIVENT (1 patients)
CORTICOSTEROIDS (1 patients)
CYCLOBENZAPRINE (1 patients)
DARVOCET-N 100 (1 patients)
DEPO-MEDROL (1 patients)
DIET (NO INGREDIENTS/SUBSTANCES) (1 patients)
DIFLUCAN (1 patients)
DUONEB (1 patients)
EFFEXOR (1 patients)
ETHAMBUTOL HYDROCHLORIDE (1 patients)
FERROUS GLUCONATE (1 patients)
FLONASO (1 patients)
FLOR-CON (1 patients)
FLOVENT (1 patients)
INSULIN (1 patients)
LACTAID (1 patients)
LITHIUM CARBONATE (1 patients)
LOVASTATIN (1 patients)
MIRAPEX (1 patients)
MONTELUKAST SODIUM (1 patients)
NEOSTIGMINE BROMIDE (1 patients)
PAROXETINE HCL (1 patients)
PEPCID (1 patients)
POTASSIUM CHLORIDE CR (1 patients)
PRAVACHOL (1 patients)
PREDNISONE (1 patients)
PREMARIN (1 patients)
PREVACID (1 patients)
PRILOSEC (1 patients)
QUINIDINE GLUCONATE (1 patients)
RANITIDINE 150MG TABLETS, UNKNOWN MANUFACTURER (1 patients)
RANITIDINE HCL (1 patients)
RANITIDINE HYDROCHLORIDE (1 patients)
RECLAST (1 patients)
ROPINIROLE (1 patients)
SINGULAIR (1 patients)
SODIUM BICARBONATE IN PLASTIC CONTAINER (1 patients)
SYNTHROID (1 patients)
TOPROL-XL (1 patients)
TRAZODONE HCL (1 patients)
TRILEPTAL (1 patients)
TRIMEBUTINE (1 patients)
ZETIA (1 patients)
Most common side effects for patients taking CLOFAZIMINE:
ARRHYTHMIA (21 patients)
NEUROPATHY PERIPHERAL (12 patients)
ANAEMIA (10 patients)
DRUG INEFFECTIVE (10 patients)
HAEMOGLOBIN DECREASED (10 patients)
LEPROSY (10 patients)
GASTROINTESTINAL DISORDER (9 patients)
PYREXIA (9 patients)
SKIN LESION (9 patients)
DIABETES MELLITUS (8 patients)
WOUND DEHISCENCE (8 patients)
ERYTHEMA (8 patients)
PEPTIC ULCER PERFORATION (8 patients)
TUBERCULOID LEPROSY (8 patients)
SUDDEN DEATH (8 patients)
OEDEMA PERIPHERAL (8 patients)
ABDOMINAL PAIN (7 patients)
ARTHRALGIA (7 patients)
PERITONITIS (7 patients)
DECREASED APPETITE (7 patients)
HAEMOLYTIC ANAEMIA (7 patients)
SKIN ULCER (7 patients)
NEUTROPENIA (7 patients)
ABDOMINAL PAIN UPPER (6 patients)
STAPHYLOCOCCAL SEPSIS (6 patients)
CUSHINGOID (6 patients)
GRANULOMA (6 patients)
PALLOR (6 patients)
LEPROMATOUS LEPROSY (6 patients)
WEIGHT DECREASED (6 patients)
NEURITIS (6 patients)
PLATELET COUNT DECREASED (5 patients)
APATHY (5 patients)
PAIN IN EXTREMITY (5 patients)
DEHYDRATION (5 patients)
DIARRHOEA (5 patients)
VOMITING (5 patients)
DYSPNOEA (5 patients)
ERYTHEMA NODOSUM LEPROSUM (5 patients)
ESCHAR (5 patients)
SKIN PLAQUE (5 patients)
SYNCOPE (5 patients)
MAJOR DEPRESSION (5 patients)
TYPE IV HYPERSENSITIVITY REACTION (5 patients)
MALAISE (5 patients)
MENTAL DISORDER (5 patients)
NAUSEA (5 patients)
ABDOMINAL PAIN LOWER (4 patients)
TORSADE DE POINTES (4 patients)
CONDITION AGGRAVATED (4 patients)
CONJUNCTIVAL DEPOSIT (4 patients)
CONJUNCTIVAL DISCOLOURATION (4 patients)
CORNEAL DEPOSITS (4 patients)
DERMATITIS (4 patients)
DRUG RASH WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (4 patients)
WHITE BLOOD CELL COUNT INCREASED (4 patients)
TACHYCARDIA (4 patients)
SKIN DISCOLOURATION (4 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (4 patients)
HALLUCINATIONS, MIXED (4 patients)
HEADACHE (4 patients)
RASH (4 patients)
IMMUNE RECONSTITUTION SYNDROME (4 patients)
SEPSIS (4 patients)
TYPE 2 LEPRA REACTION (4 patients)
RESPIRATORY FAILURE (4 patients)
NECROSIS (4 patients)
XEROSIS (4 patients)
SKIN NECROSIS (3 patients)
AGRANULOCYTOSIS (3 patients)
AIDS RELATED COMPLICATION (3 patients)
PAIN OF SKIN (3 patients)
BLOOD CREATININE INCREASED (3 patients)
RED BLOOD CELL SEDIMENTATION RATE INCREASED (3 patients)
CANDIDIASIS (3 patients)
VENTRICULAR TACHYCARDIA (3 patients)
CYANOSIS (3 patients)
DEAFNESS (3 patients)
DRUG EXPOSURE DURING PREGNANCY (3 patients)
DRUG INTOLERANCE (3 patients)
DYSPHAGIA (3 patients)
FATIGUE (3 patients)
HAEMORRHAGE (3 patients)
HEART RATE INCREASED (3 patients)
IATROGENIC INJURY (3 patients)
TUBERCULOSIS (3 patients)
LEUKOPENIA (3 patients)
MORPHOEA (3 patients)
NEURALGIA (3 patients)
PURULENT DISCHARGE (2 patients)
ACID FAST BACILLI INFECTION (2 patients)
ULNAR NEURITIS (2 patients)
ANAESTHESIA (2 patients)
APLASTIC ANAEMIA (2 patients)
TONSILLAR HYPERTROPHY (2 patients)
SKIN INDURATION (2 patients)
BLOOD ALKALINE PHOSPHATASE DECREASED (2 patients)
BLOOD BILIRUBIN ABNORMAL (2 patients)
BLOOD FIBRINOGEN INCREASED (2 patients)
BLOOD GLUCOSE DECREASED (2 patients)
PULMONARY OEDEMA (2 patients)
BLOOD SODIUM DECREASED (2 patients)
PULMONARY TUBERCULOSIS (2 patients)
BONE MARROW FAILURE (2 patients)
SMEAR SITE UNSPECIFIED ABNORMAL (2 patients)
WHITE BLOOD CELL COUNT DECREASED (2 patients)
CARDIAC FAILURE CONGESTIVE (2 patients)
CARDIAC MURMUR (2 patients)
SPUTUM CULTURE POSITIVE (2 patients)
PATHOGEN RESISTANCE (2 patients)
CHILLS (2 patients)
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2 patients)
COLON CANCER STAGE IV (2 patients)
COLOSTOMY (2 patients)
CONJUNCTIVAL DISORDER (2 patients)
CRYSTAL DEPOSIT INTESTINE (2 patients)
RASH PAPULAR (2 patients)
DAPSONE SYNDROME (2 patients)
DEEP VEIN THROMBOSIS (2 patients)
PULMONARY EMBOLISM (2 patients)
PANNICULITIS LOBULAR (2 patients)
SKIN HYPERPIGMENTATION (2 patients)
DISCOMFORT (2 patients)
DISEASE PROGRESSION (2 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (2 patients)
DRUG EFFECT DECREASED (2 patients)
DRUG INTERACTION (2 patients)
VASCULITIS NECROTISING (2 patients)
DYSAESTHESIA (2 patients)
PANCYTOPENIA (2 patients)
GANGRENE (2 patients)
GASTRITIS (2 patients)
HAEMATOCRIT INCREASED (2 patients)
HAEMATURIA (2 patients)
HAEMORRHAGIC INFARCTION (2 patients)
HAND DEFORMITY (2 patients)
PNEUMONIA (2 patients)
PERONEAL NERVE PALSY (2 patients)
HEPATIC ENZYME INCREASED (2 patients)
PATHOLOGY TEST (2 patients)
PAIN (2 patients)
POST INFLAMMATORY PIGMENTATION CHANGE (2 patients)
RENAL IMPAIRMENT (2 patients)
HYPERAESTHESIA (2 patients)
RECTAL HAEMORRHAGE (2 patients)
HYPERSENSITIVITY (2 patients)
HYPERTENSION (2 patients)
HYPOAESTHESIA (2 patients)
HYPOALBUMINAEMIA (2 patients)
HYPOCHROMIC ANAEMIA (2 patients)
POLYNEUROPATHY (2 patients)
OROPHARYNGEAL PLAQUE (2 patients)
HYPOTONIA (2 patients)
INTESTINAL OBSTRUCTION (2 patients)
INTUBATION (2 patients)
SCROTAL GANGRENE (2 patients)
LEUKOCYTOSIS (2 patients)
LIVER PALPABLE SUBCOSTAL (2 patients)
LUNG DISORDER (2 patients)
LYMPHADENOPATHY (2 patients)
LYMPHOCYTIC INFILTRATION (2 patients)
MARROW HYPERPLASIA (2 patients)
MEAN CELL HAEMOGLOBIN CONCENTRATION DECREASED (2 patients)
MEAN CELL VOLUME INCREASED (2 patients)
MENTAL STATUS CHANGES (2 patients)
OROPHARYNGEAL PAIN (2 patients)
METASTASES TO LIVER (2 patients)
METHAEMOGLOBINAEMIA (2 patients)
NERVOUS SYSTEM DISORDER (2 patients)
NEUTROPHILIA (2 patients)
NODULE (2 patients)
NORMAL NEWBORN (2 patients)
OEDEMA (2 patients)
OPTIC NEUROPATHY (2 patients)
ACHLORHYDRIA (1 patients)
AGITATION (1 patients)
ALANINE AMINOTRANSFERASE INCREASED (1 patients)
BILIARY TRACT DISORDER (1 patients)
BLISTER (1 patients)
BLOOD FIBRINOGEN DECREASED (1 patients)
CHEST PAIN (1 patients)
CHEST WALL MASS (1 patients)
CONFUSIONAL STATE (1 patients)
CONVULSION (1 patients)
EMOTIONAL DISTRESS (1 patients)
ENTERITIS (1 patients)
EOSINOPHILIA (1 patients)
EPISTAXIS (1 patients)
ERYTHEMA NODOSUM (1 patients)
ESCHERICHIA INFECTION (1 patients)
FAECAL OCCULT BLOOD (1 patients)
FEEDING TUBE COMPLICATION (1 patients)
GASTROENTERITIS (1 patients)
GASTROINTESTINAL HAEMORRHAGE (1 patients)
GASTROINTESTINAL INFLAMMATION (1 patients)
GENITAL HAEMORRHAGE (1 patients)
GENITAL ULCERATION (1 patients)
GINGIVAL BLEEDING (1 patients)
GINGIVAL DISORDER (1 patients)
GLOMERULONEPHRITIS ACUTE (1 patients)
GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFICIENCY (1 patients)
GRAND MAL CONVULSION (1 patients)
GRANULOCYTE COUNT DECREASED (1 patients)
HAEMATEMESIS (1 patients)
MITOCHONDRIAL TOXICITY (1 patients)
MUCOSAL ULCERATION (1 patients)
MULTIPLE-DRUG RESISTANCE (1 patients)
MUSCLE SPASMS (1 patients)
MYDRIASIS (1 patients)
NEUROTOXICITY (1 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.


Recent FactMed Activity for CLOFAZIMINE


Issue Description / Topic Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about ACHLORHYDRIA and CLOFAZIMINE, post it here. You may receive a response from a fellow patient - or a leading expert in the field.
Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking CLOFAZIMINE, post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.
Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in CLOFAZIMINE. This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.
We are currently accepting registration for CLOFAZIMINE experts. If you are a healthcare provider experienced in prescribing CLOFAZIMINE, please register here.
giCould not connect: